Primarily, Ascentage hopes to leverage the IPO proceeds to advance its pipeline. Around $50 million to $60 million, for instance, will help the biotech pursue approval for its BCL-2 blocker ...

The biotech firm's mRNA-1018 candidate posted positive results in a Phase 1/2 study launched in 2023. Moderna plans to move mRNA-1018 to a Phase 3 trial. Shares of Moderna (MRNA) took off Tuesday ...

In 2019, Stan­ford Uni­ver­si­ty pro­fes­sor Irv Weiss­man and a col­league pub­lished a pa­per that rep­re­sent­ed a new way to tar­get some ag­gres­sive can­cers.

Odyssey Therapeutics and Sionna Therapeutics have filed IPO paperwork, swelling the pack of startups that will provide an early look at how receptive public investors could be to biotech listings ...

Prolium was set up by RTW in 2024. Last year also saw the New York-based investment fund involved in the launch of obesity biotech Kailera Therapeutics, which RTW said at the time was the fourth ...

The Biotech Beach Hotbed includes San Diego, Los Angeles and the surrounding (Torrey Pines, Thousand Oaks) regions of Southern California. SoCal is well-known for its sprawling beaches and ...

But local biotech leaders see signs of change in 2025. Amid tough biotech industry market conditions last year, investors and Big Pharma companies were more likely to make deals with later-stage ...

The Chi­na-to-US ex­per­i­men­tal med­i­cine pipeline is bal­loon­ing: yet an­oth­er US-based biotech formed around a can­di­date from Chi­na’s Keymed Bio­sciences on Mon­day.

Prolium will make a $17.5m upfront payment, with potential milestone payments totalling $502.5m. Credit: uniquepixel via Getty Images. Investment company RTW Investments has launched a new biotech ...